

Institutional Biosafety Committee
University of Arizona
February 18, 2026
Zoom
10:00AM – 11:00AM
Meeting Minutes

Members Present: Dr. Michael Riehle, Dr. David Besselsen, Ceasar Ramirez, Dr. Judith Brown, Patricia Gundy, Dr. Mrinalini Kala, Jennifer Uhrlaub, Hien Trinh, Marcy Milbrandt, , , Dr. Anita Koshy, Dr. Lynn Stone

Non-members' Present: None.

Members Absent: Lauren Melcher, Dr. Jonathan Sexton, Dr. Kathryn O'Connell

The meeting was called to order at 10:00 AM

1. Review of the previous meeting minutes: January 21, 2026
2. Biosafety Level 2 (Non-rNucleic Acid) Applications
 - a. Jeong-Yeol Yoon, PhD, Agricultural & Biosystems Engineering, Approval No. 12079
Protocol Title: Cell Culture Protocol
Agents: Cell Line (Human- HPV positive)

The Committee approved your protocol.

- b. Samantha Harris, PhD, Molecular & Cellular Biology, Approval No. 12235
Protocol Title: Regulation of muscle contraction by myosin binding protein-C
Agents: Tissue (Human)

The Committee approved your protocol and wanted to ensure that your lab workers and you are aware that Occupational Health offers free hepatitis vaccine(s) and/or titers. Please contact Occupational Health, (520) 621-5643.

3. Biosafety Level 2 (Non-Exempt-rNucleic Acid) Application
 - a. Katharina Schimmel, PhD, CoM-PHX, Approval No. 11117
Protocol Title: Understanding and targeting pulmonary arteriovenous malformations
Agents: Tissue (Mouse), Primary Cells (Humans and Mouse), Induced Pluripotent Stem Cells (Humans),
Cell Line (Human and Mouse)

This protocol falls under NIH Guideline III-D.

The Committee approved your protocol and wanted to ensure that your lab workers and you are aware that Occupational Health offers free hepatitis vaccine(s) and/or titers. Please contact Occupational Health, (520) 621-5643.

4. Advisements

- a. Colleen Janczak, PhD, Surgery, Approval No. 12494

Protocol Title: Suppression of cytokine release from Human peripheral blood mononuclear cells by anti-inflammatory agents.

Agents: Cell Line (Human- U-937: leukemia cell line)

The Committee reviewed the additional agent to the BSL2 approval.

5. Compliance Review Issues

- a. The audit report for January through February 2026.

- b. Incident(s): None.

- BSO spoke about a non-biosafety incident regarding a needlestick from a common area bathroom by a person that left a testosterone syringe with needle. BSO dropped off sharps containers to the building and the building manager is contacting Facilities Management to install sharps containers in each bathroom.

6. Compliance Review Issues

- c. The audit report for December 2025 through January 2026

- d. Incident(s): None.

7. Old Business

- a. Dr. Li- CHIK update using UV cross-linking inactivation

- Committee members reviewed the results and approved this method of inactivation.

- b. Dr. Negrey- no response on tabled protocol dealing with NHPs

- c. Dr. Ikner- see response

- Committee members reviewed and approved the responses sent by PI.

- d. Dr. Kaddouh- no response on tabled human subject protocols

8. New Business

- a. New BSL3 protocol for MERS

- Committee members discussed and agreed to have the PI wanting to work with MERS to submit a new protocol as the protocol is different than previously approved BSL3 protocols.

The next meeting is scheduled for March 18, 2026, via Zoom.

The meeting was adjourned at 10:57AM.

Prepared by: Ceasar Ramirez

Reviewed by:

A handwritten signature in blue ink, appearing to read "Michael Riehle". The signature is fluid and cursive, with the first name "Michael" and last name "Riehle" clearly distinguishable.

Michael Riehle, PhD
Chair, Institutional Biosafety Committee